| Hazard Information | Back Directory | [Uses]
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer[1][2][3]. | [in vivo]
Tisotumab vedotin can cause immunogenic tumor cell death, promote activation of F4/80+ and CD11c+ innate immune cells, and recruit them into xenograft tumors[1].
Tisotumab vedotin (2 mg/kg; once daily; 25 days) has anti-tumor activity in a mouse model of pancreatic cancer[4]. | Animal Model: | HPAF-II, SCID mice[4]. | | Dosage: | 2 mg/kg | | Administration: | Once daily; 25 days | | Result: | Decreased the tumor volume over the 3-week window. |
| [References]
[1] Gray E, et al. Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell deathJournal for ImmunoTherapy of Cancer 2020;8.
[2] Alley S C, et al. Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro[J]. Cancer Research, 2019, 79(13_Supplement): 221-221.
[3] Luu K, et al. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin. J Oncol Pharm Pract. 2023 Mar;29(2):441-449. DOI:10.1177/10781552221139775
[4] Rubahamya B, et al. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Sci Adv. 2024 May 31;10(22):eadk1894. DOI:10.1126/sciadv.adk1894 |
|
| Company Name: |
bioleaper
|
| Tel: |
4000880777 17585207275 |
| Website: |
www.bioleaper.com/ |
|